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LETTERSTOTHEEDITOR 127Our results showed increased MMP-9 levels in
serum depending on the clotting surface of the
tubes used for sample collection compared to heparin
and EDTA plasma (Fig. 1). Increased values in serum
are supposedly caused by the release of MMP-9 during
platelet activation and clottingprocess.These important
preanalytical conditions should be considered
in the interpretation of increased MMP levels. Hrabec et
al. did not clearly distinct between serum or plasma
samples that may lead to misinterpretations. This
point would ¢t in their conclusion which assumed that
mechanisms additional to enzyme over-expression in
lung cancer may be responsible for the enhanced MMP
levels.
The pre-analytical sampling is therefore an important
feature for the MMP measurement in the blood regard-
less of the method which is ¢nally used for the enzyme
quanti¢cation.Webelieve that it is necessary to consider
this fact in future studies on the clinical validity of MMP
measurements in blood.
M. JOHN,U.OLTMANNS,C.WITT and K. JUNG
Department of Pneumology and
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Re: Elevated level of circulatingmatrix
metalloproteinase-9 inpatientswith lung
cancer (Respir Med 2001; 95: 1^4): a replyWe are aware of the letter by Dr M. John and colleagues
to the Editor of RespiratoryMedicine aswell as the results
of their study on the role of specimen collection in the
measurement of matrix metalloproteinases (MMPs) and
matrix metalloproteinase inhibitors (TIMPs) publishedearlier (1).We of course agree with Dr John that appro-
priate selection of specimens is very important for cor-
rect evaluation of MMPs activities in blood.
The studies conducted in other laboratories in the
1990s showed that serum or plasma type IV collagenase
levels are signi¢cantly elevated in many neoplastic dis-
eases and it has been suggested that the rise in circulat-
ing MMP-2 and/or MMP-9 levels in cancer patients
re£ects enhanced secretion of these enzymes in tumour
area (2,3). Using a zymographic test we analysed the
type IV collagenases levels in serum samples of lung can-
cer patients and healthy volunteers, hoping that MMP-2
activity would be elevated in lung cancer sera, since our
previous study showed that this enzyme is predomi-
nantly over-expressed in lung cancer tissue as compared
to normal lung parenchyma (4). However, the serum le-
vels of MMP-2 in lung cancer patients were similar to
those of healthy donors, whereas MMP-9 levels were
3?59-fold higher in lung cancer.We presented the results
of this study in our article (5). Since the di¡erences be-
tween normal and cancer sera concerned MMP-9, but
not MMP-2, we took into consideration the results of
the study reported by Dr John and colleagues (6) and
tested these activities also in plasma samples. In the zy-
mographic test we compared the serum and plasma le-
vels of type IV collagenases from the same individuals
(lung cancer patients andhealthy volunteers).Forplasma
preparation venous blood samples were collected into
lithium heparin-coated plastic tubes (Vacuette-Greiner
Labortechnik, Ko¤ dzŁ , Poland). These results were also
presented in our article (5).We showed that MMP-2 le-
vels tested in serum and plasma specimens were similar
in the range of analytical precision and did not di¡er be-
tween both groups tested (normal and cancer), whereas
MMP-9 levels tested in serumwere about two foldhigher
than in plasma samples. However, the MMP-9 activities
tested in plasma of lung cancer patients were 3?42-fold
higher than in plasma from normal individuals.Thus, the
di¡erences in MMP-9 levels between cancer and normal
samples tested in plasmawere similar to those obtained
for serum.Wewish to emphasize that in each case com-
parisons were made between consistent specimens (i.e.
MMP-9 activities in cancer plasma samples were com-
pared with normal plasma samples and MMP-9 activities
in cancer serum samples were compared with normal
serum). In the ¢rst version of our manuscript submitted
to Respiratory Medicine we inserted a ¢gure illustrating
the di¡erences between serum and plasma levels of
these enzymes evaluated by zymography. However, by
request from the Editor, we shortened our article and
this ¢gure was not published. Now, for a better illustra-
tion of the results of the study we present this ¢gure
(Fig.1).
We do not believe that increased MMP-9 values ob-
served in serum are a result of releasing of this enzyme
from platelets during their activation and clotting pro-
FIG. 1. An example of zymographic detection of serum and plasma MMP-2 and MMP-9 species in healthy volunteers (a,c) and lung
cancer patients (b,d): lane a, standard, commercial MMP-2 and MMP-9; lane b, serum samples; lane c, plasma samples.
FIG. 2. Zymographic pattern of cell lysates: lane a, platelets
(1105mlÿ1); lane b, standard MMP-2 and MMP-9; lane c,PMNL
(1108 cells mlÿ1).
128 RESPIRATORYMEDICINEcesses as was suggested by Jung et al. (6). Lindenmeyer et
al. (7) were unable to demonstrate of MMP-2 or MMP-9
activities in medium after incubation of thrombin-acti-
vated platelets at the concentration of 4108 cellsmlÿ1,
although Sawickietal. (8) showed thatMMP-2 is released
fromplatelets during their activation.Using zymography
we analyzed cell lysates of polymorphonuclear leuko-
cytes (PMNL) and platelets and showed (Fig. 2) that
whereas granulocytes are able to express MMP-9, the
platelets express little MMP-2 only. So, we suppose that
the platelets are not a source of MMP-9 in serum speci-
mens.However, it has been shown (7) that activatedpla-
telets are able to stimulate breast cancer cells MDA-
MB231to secrete MMP-9, and it is not excluded that also
some blood cells (e.g. PMNL) are stimulated by activated
platelets to release MMP-9 during blood clotting. How-
ever, in the experiment performed by Lindenmeyer et
al. (7) augmented release of MMP-9 by MDA-MB231cells
was preceded by augmented synthesis of this enzyme.
Stimulation of synthesis of new particles of the enzymevia activated platelets followed by its release needs, of
course, considerably more time than it is required for
blood clotting. So, to date, the reasons for higher MMP-
9 levels in serum than in plasma are unclear.
E.HRABEC,M. STREK,DNOWAK ANDZ.HRABEC
Department of Medical Biochemistry and
Department of Clinical Physiology,
Medical University of Lodz,
Lodz, Poland
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Sir,
Universally low spirometry values in
respiratory outpatients
An increasingly important part of a chest physicians
workload is runningoutreach clinics. As formal lung func-
tion laboratories are often not available at these commu-
nity hospitals, it is often the outpatient nurses who
perform spirometry on patients prior to their consulta-
tion.The most common spirometer being used in these
clinics is the bellows vitalograph.
Atone of these clinics recently,wenoticed thatnurse-
recorded spirometry in patients was consistently lower
than previously recorded values, despite the fact that
peak expiratory £ow rates were similar and the patients
were stable.
Inspecting the bellows vitalograph we found numer-
ous cracks in the hosing (Fig.1). This had been caused by
repeated autoclaving of the hose to comply with infec-
tion control requirements. Cracking of the tubing sec-
ondary to autoclaving is an important cause of error,
which may not be obvious unless the tubing is checked
carefully.N. A.MASKELL AND J.G. PRIOR
Department of Thoracic Medicine,




Re: Evaluation of an inspiratorymuscle
trainer in healthy humans (Respir Med
2001; 95: 526^531)
It was with a combination of astonishment and disbelief
that I read the recently published paper by Hart et al. in
the June edition of Respiratory Medicine.
The ¢rst thing that struck me was the unusually
speci¢c nature of the report. The authors had singled
out a particular brand of equipment for very harsh criti-
cism.The equipment in question (the Powerbreathes) is
only one of a number of such training devices now avail-
able. I was then astonished to ¢nd that as the inventor of
this device, I was also singled out for negative comment.
The ¢rst paragraph under the heading ‘Signi¢cance of
Results’ (p530) reads like something from a tabloid
newspaper expose, rather than a professional journal.
This paragraph is extraordinary and I have never seen
anything like it in a professional journal before; its tone
and content go far beyond academic rivalry. Moreover,
the authors substantiate their viewswith a negative ¢nd-
ing that is statistically £awed (see attached critique).
Failings in the author’s experimental design have led di-
rectly to their negative comment inyour Journalwith re-
spect to the e⁄cacy of the Powerbreathes; this is
unacceptable.
We believe that Hart et al.’s study is fundamentally
£awed as follows. The single most damning factor with
respect to this paper’s credibility is one of statistical in-
adequacy. The authors base their conclusion that the
Powerbreathes does not improve inspiratory muscle
function on one observation, viz., that twitch Pdi
showedno statistically signi¢cant alteration following in-
spiratory muscle training (IMT). By the authors’ own ad-
mission, the reliability of twitch Pdi is extremely poor
(p530), requiring unreasonably large subject numbers to
identify statistically signi¢cant changes. A technique that
requires 234 subjects to detect a 10% e¡ect with 0?8
power at an a-level of 0?05 is too unreliable to be useful
in any study with a repeated measures design. The
authors must state what magnitude of e¡ect size is re-
quired to produce an increase in twitch Pdi that is statis-
tically signi¢cant using 12 subjects. In any case, it should
have been obvious to the authors that it was statistically
impossible to identify a signi¢cant change in twitch Pdi
using six subjects per group. Accordingly, the e⁄cacy of
the Powerbreathes was impossible to prove using their
methodology.
It is extraordinary to conduct a power analysis only to
dismiss its result when it suggests that an unreasonably
large number of subjects are required to avoid a type 2
error.This de¢es logic and scienti¢c reasoning.Theresult
